BioNexus Gene Lab Corp. (BGLC) Fair Value 2026

BGLC · Specialty Chemicals ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.5 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (40/100)

Quick Summary — As of 2026-08-28, BioNexus Gene Lab Corp. (BGLC) trades at $1.55. QOC: 5.5/10. Value Trap Risk: 40/100 (WARN). 1/13 models active.

Key Facts

Ticker
BGLC
Price
$1.55
Quality Score
5.5/10
Value Trap Risk
40/100
Models Active
1/13
Last Updated
Strength: Dynamic NAV suggests +74.2% upside with 52% confidence
Risk: Value Trap score of 40 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give BGLC?

1 Intrinsic Value Models vs. Current Price ($1.55)

Core Models (Unlocked)
Model Fair Value Upside
Asset-Based · High Conviction
 $2.70 +74.2%

All Models Active

All 1 models are displayed above.

What Is BioNexus Gene Lab Corp. (BGLC) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, BioNexus Gene Lab Corp.'s intrinsic value is estimated at a median fair value of $2.70. At a current market price of $1.55, 1 of 1 active valuation models identify upside potential, projecting a median implied return of +74.2%.

What Do the Models Say About BGLC?

1 of 13 models are currently active for BGLC. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does BGLC Rank in Specialty Chemicals?

Among 70 Specialty Chemicals stocks, BGLC ranks #53 by Quality of Company score. CirclFi's QOC score of 5.5/10 evaluates 32 fundamental signals. A score of 5.5 reflects mixed fundamentals.

See all Most Undervalued Specialty Chemicals Stocks →

BioNexus Gene Lab Corp.'s positioning within the Specialty Chemicals segment means that working capital efficiency plays an outsized role in fundamental analysis. The sector's unique characteristics — including automation and productivity gains — shape both the opportunity set and risk profile.

Is BGLC a Value Trap?

CirclFi's Value Trap algorithm assigns BGLC a score of 40/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for BioNexus Gene Lab Corp.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, BioNexus Gene Lab Corp. earns a quality score of 5.5/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BGLC valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BGLC's 1 active models, average confidence is 52%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy BioNexus Gene Lab Corp. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Specialty Chemicals Stocks Should You Also Analyze?

11 related Specialty Chemicals stocks with 13-model coverage

RLEARubber Leaf Inc.QOC 5.8ASHAshland Inc.QOC 5.4BLGOBioLargo, Inc.QOC 5.9CITRCitroTech Inc.QOC 5.3PRMPerimeter Solutions, Inc.QOC 6.0LOOPLoop Industries, Inc.QOC 5.3BONBon Natural Life LimitedQOC 1.9AVNTAvient CorporationQOC 8.1MATVMativ Holdings, Inc.QOC 6.9ODCOil-Dri Corporation of AmericaQOC 9.2RPMRPM International Inc.QOC 9.0

Read investment analysis: RLEA · ASH · BLGO · CITR · PRM · LOOP · BON · AVNT · MATV · ODC · RPM

Which Other Stocks Have a Similar Quality Score to BGLC?

7 companies across all industries closest to BGLC’s Quality of Company score of 5.5/10.

ALMAlmonty Industries Inc.QOC 5.5SMCSummit Midstream CorporationQOC 5.5PIACPrinceton Capital CorporationQOC 5.5SPRYARS Pharmaceuticals, Inc.QOC 5.5ASBPAspire Biopharma Holdings, Inc.QOC 5.5ATHRAether Holdings, Inc.QOC 5.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ALM · SMC · PIAC · SPRY · ASBP · ATHR · NVDA

Where Does BGLC Sit in CirclFi's Specialty Chemicals Rankings?

BGLC is ranked against every other Specialty Chemicals stock CirclFi covers in each of these screens.

See all Specialty Chemicals stocks ranked →

What Else Do Investors Ask About BioNexus Gene Lab Corp.’s Valuation?

What is BioNexus Gene Lab Corp.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for BioNexus Gene Lab Corp. (BGLC). The Quality of Company score is 5.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BGLC overvalued or undervalued right now?

At $1.55, 1 of 1 active models suggest BGLC may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits BioNexus Gene Lab Corp.'s business model in Specialty Chemicals.

What does a Quality of Company score of 5.5 mean for BGLC?

BioNexus Gene Lab Corp.'s QOC of 5.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on BGLC?

CirclFi analyzes BGLC with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is BGLC a value trap in 2026?

BioNexus Gene Lab Corp.'s Value Trap score is 40/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns BioNexus Gene Lab Corp. (BGLC) a Quality of Company score of 5.5/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/BGLC/ · Methodology
Primary sources for this BGLC valuation
  • Financial statements: BioNexus Gene Lab Corp. 10-K and 10-Q filings on SEC EDGAR (CIK 0001737523) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BGLC as of ; valuations recomputed .